| Literature DB >> 30593548 |
Han Qi1, Bin Liu1, Chunyue Guo1, Zheng Liu1, Han Cao1, Kuo Liu1, Weiping Sun2, Ling Zhang1.
Abstract
PURPOSE: The systemic epidemiology of salt sensitivity (EpiSS) study aims to combine molecular biology, epidemiology and bioinformatics methods to discover the potential causes of salt sensitivity of blood pressure (SSBP) using single-nucleotide polymorphisms in the genome and non-coding RNAs in the transcriptome to uncover both the genetic and environmental factors of SSBP. PARTICIPANTS: Between July 2014 and July 2016, we enrolled adults from 11 study centres in Beijing and Liaoning Province; participants were of the Han population and were 35-70 years of age. We collected blood samples, spot urine samples and 24-hour urine samples, in addition to baseline data on demographics, health-related lifestyle factors, chronic diseases, family history of illness and anthropometric information through face-to-face interviews using a standardised questionnaire. EpiSS uses the modified Sullivan's acute oral saline load and diuresis shrinkage test (MSAOSL-DST) to evaluate the effects of salt on blood pressure. FINDINGS TO DATE: In total, 2163 participants were included in the EpiSS, of which 2144 participants completed the questionnaire, 2120 (98.0%) completed the MSAOSL-DST and 2083 (96.3%) provided a 24-hour urine sample. A total of 2057 participants (1501 women and 556 men) completed all the steps of the investigation and were included in the analysis. Among them, 583 (28.3%) subjects were classified as having salt sensitivity of blood pressure, and 1061 (51.6%) had hypertension. FUTURE PLANS: The next step of our study is to evaluate the incidence of cardiovascular disease in the participants. Biennial follow-up, including face-to-face questionnaire surveys, laboratory measurements of blood, urinary creatinine, glomerular filtration rate and anthropometric measurements, will occur two additional times. DNA and RNA will be collected for subsequent genetic biomarker studies. We plan on screening the salt-sensitive-related gene loci and non-coding RNAs based on relative environmental risk factors. TRIAL REGISTRATION NUMBER: ChiCTR-EOC-16009980; Pre-results. © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: blood pressure; dietary sodium; epidemiology; genes; salt sensitivity
Mesh:
Substances:
Year: 2018 PMID: 30593548 PMCID: PMC6318536 DOI: 10.1136/bmjopen-2018-023042
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Inclusion/exclusion criteria for normal blood pressure participants
| Inclusion criteria | Exclusion criteria |
|
Local resident for more than 5 years Age 35–70 years Han nationality Independent individuals Those from the same community where patients with primary hypertension were selected SBP <140 mm Hg and DBP <90 mm Hg, without antihypertensive treatment Willingness to volunteer to participate in the trial and sign the informed consent form |
Use of any antihypertensive drug in the previous 24 hours Clinical diagnosis of cardiovascular disease, kidney disease, liver disease or malignant tumour Pregnant women Self-adherence to a low-sodium diet Inability or unwillingness to participate in the study or sign the informed consent form |
DBP, diastolic blood pressure; SBP, systolic blood pressure.
Inclusion/exclusion criteria for hypertension participants
| Inclusion criteria | Exclusion criteria |
|
Local resident for more than 5 years Age 35–70 years Han nationality Independent individuals Early stage of essential hypertension, 160 mm Hg>SBP≥140 mm Hg and (or) 100 mm Hg>DBP≥90 mm Hg, according to the definition standard of the 2010 Chinese hypertension guidelines No secondary hypertension Willingness to volunteer to participate in the trial and sign the informed consent form |
Patients with secondary stage and above hypertension (SBP >160 mm Hg and (or) DBP >100 mm Hg) Use of any antihypertensive drugs in the previous 1 month Clinical diagnosis of cardiovascular disease, kidney disease, liver disease or malignant tumour Pregnant women Self-adherence to a low-sodium diet Inability or unwillingness to participate in the study or sign the informed consent form |
DBP, diastolic blood pressure; SBP, systolic blood pressure.
Figure 1Process of the modified Sullivan’s acute oral saline load and diuresis shrinkage test (MSAOSL-DST).
Figure 2Flow chart of participant enrolment. EpiSS, systemic epidemiology of salt sensitivity study; MSAOSL-DST, modified Sullivan’s acute oral saline load and diuresis shrinkage test.
Baseline sociodemographic characteristics, health-related lifestyle factors, anthropometric information and laboratory measurements
| Characteristics | Total | Hypertensive | Normotensive | P value |
| Age (years)* | 59.00 (54.00–63.00) | 58.00 (52.00–63.00) | 60.00 (55.00–64.00) | <0.001† |
| Gender (female, %)‡ | 1501 (73.0) | 747 (70.4) | 754 (75.7) | 0.007† |
| High school graduate and above (%)‡ | 983 (50.2) | 478 (49.6) | 505 (50.8) | 0.621 |
| Current cigarette smoking (%)‡ | 310 (15.2) | 177 (17.0) | 133 (13.4) | 0.026† |
| Current alcohol consumption (%)‡ | 963 (47.3) | 492 (47.3) | 471 (47.3) | 0.990 |
| Waist circumference (cm)* | 88.00 (82.00–94.00) | 90.00 (85.00–96.80) | 86.00 (79.00–90.88) | <0.001† |
| Hip circumference (cm)* | 98.82 (94.00–103.50) | 100.80 (96.00–105.65) | 97.00 (93.00–101.00) | <0.001† |
| BMI (kg/m2)* | 25.92 (23.85–28.15) | 26.84 (24.86–29.02) | 25.15 (23.01–26.95) | <0.001† |
| WHR* | 0.89 (0.85–0.93) | 0.89 (0.86–0.94) | 0.88 (0.84–0.92) | <0.001† |
| FBG (mmol/L)* | 5.42 (4.99–6.18) | 5.59 (5.06–6.46) | 5.29 (4.92–5.90) | <0.001† |
| TC (mmol/L)* | 5.04 (4.35–5.73) | 4.99 (4.20–5.70) | 5.09 (4.46–5.77) | 0.003† |
| TG (mmol/L)* | 1.63 (1.12–2.48) | 1.68 (1.17–1.68) | 1.55 (1.09–2.42) | 0.019† |
| LDL-C (mmol/L)* | 2.15 (1.48–2.86) | 1.93 (1.36–2.86) | 2.23 (1.57–2.86) | 0.001† |
| HDL-C (mmol/L)* | 1.44 (1.13–2.40) | 1.48 (1.13–2.40) | 1.39 (1.13–2.45) | 0.296 |
| Baseline blood pressure | ||||
| SBP (mm Hg)* | 135.00 (122.50–147.50) | 142.00 (131.13–152.00) | 126.50 (115.50–138.50) | <0.001† |
| DBP (mm Hg)* | 78.50 (71.50–86.00) | 82.00 (75.50–89.50) | 74.50 (68.00–81.00) | <0.001† |
| MAP (mm Hg)* | 97.50 (89.33–105.83) | 102.00 (95.56–109.46) | 91.75 (84.88–100.13) | <0.001† |
| Baseline spot urine sample | ||||
| Sodium concentration (mmol/L)* | 131.35 (97.78–162.00) | 125.00 (94.00–157.00) | 136.00 (104.00–164.78) | <0.001† |
| Potassium concentration (mmol/L)* | 63.50 (41.80–89.10) | 62.23 (42.04–87.36) | 65.58 (41.42–90.53) | 0.319 |
| 24-hour urine sample | ||||
| Urine volume (L)* | 1.41 (1.00–2.00) | 1.57 (1.00–2.20) | 1.20 (0.80–1.80) | <0.001† |
| Sodium excretion (mmol/day)* | 103.50 (70.18–146.03) | 103.25 (71.00–141.25) | 103.70 (69.00–151.15) | <0.001† |
| Potassium excretion (mmol/day)* | 31.02 (21.60–44.89) | 28.65 (20.45–39.70) | 34.20 (23.00–51.16) | <0.001† |
| Estimated salt intake (g/day)* | 8.01 (5.25–11.47) | 8.97 (6.31–12.50) | 6.87 (4.57–10.50) | <0.001† |
| Disease and family history | ||||
| Diabetes (%)‡ | 327 (15.9) | 224 (21.2) | 103 (10.3) | <0.001† |
| Obesity (%)‡ | 538 (26.2) | 378 (35.6) | 160 (16.1) | <0.001† |
| Family history of hypertension (%)‡ | 1145 (57.8) | 714 (72.4) | 431 (43.3) | <0.001† |
| Family history of diabetes (%)‡ | 527 (26.6) | 285 (27.7) | 242 (24.3) | 0.084 |
| Salt-sensitive blood pressure | ||||
| Salt sensitive (%)‡ | 583 (28.3) | 302 (28.5) | 281 (28.2) | 0.900 |
*Mann-Whitney U test.
†Hypertension group compared with non-hypertension group, p<0.05.
‡χ2 test.
BMI, body mass index; DBP, diastolic blood pressure; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MAP, mean arterial pressure; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; WHR, waist:hip ratio.